NeuroNate said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
CarlaRPh_TPA said:Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…
Vendor communication red flags for compounded supply:
- Won't provide COA before purchase — walk away
- Claims "100% pure" without analytical data — unrealistic
- No physical address or phone number — accountability matters
- Pushes you to buy more than you need — pressure tactics
- Won't answer questions about their compounding process — transparency is key
- Payment only via crypto or wire transfer — legitimate pharmacies accept cards
A legitimate compounding pharmacy operates like a healthcare business, not a gray market dealer.
Dr.RenalNash said:A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.
For compounded supply users considering compounded for the first time: here's a step-by-step guide:
- Get a prescription from your doctor (telehealth counts)
- Research 503B compounding pharmacies with good community reviews
- Verify their FDA registration and inspection history
- Request a COA for your specific compound before ordering
- Start with a 1-month supply to test
- Consider sending a sample to Janoshik for independent verification
- Track your response compared to brand (if you were on it previously)
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsA narrower follow-up, since the general answer is now clear:
Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?
Closing the loop on my own question.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.